A Current Landscape on Alport Syndrome Cases: Characterization, Therapy and Management Perspectives.

Abstract

Alport syndrome (AS) is a rare genetic disorder categorized by the progressive loss of kidney function, sensorineural hearing loss and eye abnormalities. It occurs due to mutations in three genes that encode for the alpha chains of type IV collagen. Globally, the disease is classified based on the pattern of inheritance into X-linked AS (XLAS), which is caused by pathogenic variants in COL4A5, representing 80% of AS. Autosomal recessive AS (ARAS), caused by mutations in either COL4A3 or COL4A4, represents 15% of AS. Autosomal dominant AS (ADAS) is rare and has been recorded in 5% of all cases due to mutations in COL4A3 or COL4A4. This review provides updated knowledge about AS including its clinical and genetic characteristics in addition to available therapies that only slow the progression of the disease. It also focuses on reported cases in Saudi Arabia and their prevalence. Moreover, we shed light on advances in genetic technologies like gene editing using CRISPR/Cas9 technology, the need for an early diagnosis of AS and managing the progression of the disease. Eventually, we provide a few recommendations for disease management, particularly in regions like Saudi Arabia where consanguineous marriages increase the risk.

• Authors: Nahed N Mahrous, Yahya F Jamous, Ahmad M Almatrafi, Deema I Fallatah, Abdulrahman Theyab, Bayan H Alanati, Suliman A Alsagaby, Munifa K Alenazi, Mohammed I Khan, Yousef M Hawsawi
• Journal: Biomedicines (Biomedicines) Vol. 11 Issue 10 (Oct 12 2023) ISSN: 2227-9059 [Print] Switzerland
• PMID: 37893135 (Publication Type: Journal Article, Review)